Parkinson’s as I see it: we invested tons of money to investigate dopamine agonists but couldn’t find any better than dopamine (in the form of l-dopa). The only problem is it’s pharmakokinetics. As for neurotoxicity, I still believe that the small doses used nowadays (as compared to earlier decades or in mice) fare quite well.
So we spend some time reviewing the history of levodopa and the basic pharmacology.
Here are some references:
- From the Movement Disorders Society
- An article in the Journal of Neurology 2010
- A review in Movement Disorders 2008 of the history of l-dopa
- and one about it’s pharmacology